gene editing

Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Xconomy
ViaCyte
diabetes
gene editing
stem cells
Flag link:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia
earnings
Flag link:
How CRISPR can help us win the fight against the pandemic
How CRISPR can help us win the fight against the pandemic
MedCity News
CRISPR
gene editing
pandemic
COVID-19
R&D
Flag link:
Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Motley Fool
Sangamo Therapeutics
Biogen
gene therapy
gene editing
Parkinson's Disease
Alzheimer's disease
Flag link:
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
Xconomy
LogicBio Therapeutics
gene editing
clinical trials
methylmalonic acidemia
FDA
Flag link:
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Xconomy
IPOs
Beam Therapeutics
gene editing
Flag link:
This Start-up Might Be the Next Gene Editing IPO
This Start-up Might Be the Next Gene Editing IPO
Motley Fool
gene editing
Beam Therapeutics
IPOs
CRISPR
Flag link:
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
More CRISPR Stock Catalysts Ahead
More CRISPR Stock Catalysts Ahead
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Flag link:
Cellectis gene editing patent upheld in Europe
Cellectis gene editing patent upheld in Europe
Seeking Alpha
gene editing
Europe
Cellectis
patents
Flag link:
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Investors Business Daily
CRISPR Therapeutics
gene editing
CRISPR
beta thalassemia
sickle cell disease
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
A Look at America’s First CRISPR Clinical Trial
A Look at America’s First CRISPR Clinical Trial
Xtalks
CRISPR
gene editing
clinical trials
Flag link:
First use of CRISPR against cancer in patients clears early safety hurdles
First use of CRISPR against cancer in patients clears early safety hurdles
Stat
gene editing
CRISPR
patient safety
cancer
Flag link:
A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal
A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal
Endpoints
Vertex Pharmaceuticals
CRISPR
gene editing
CTX001
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
gene editing
Flag link:
Gene-Editing Company Beam Seeks $100 Million IPO
Gene-Editing Company Beam Seeks $100 Million IPO
BioSpace
Beam Therapeutics
IPOs
gene editing
Flag link:
Can Synthetic Biology Make Insulin Faster, Better and Cheaper?
Can Synthetic Biology Make Insulin Faster, Better and Cheaper?
Forbes
diabetes
insulin
drug pricing
Genentech
gene editing
Flag link:

Pages